


Supplementary Figure 1. The structure of Taxol and NMR spectra of the catalytic products of the recombinant DBAT (a. The structure of Taxol. b. The ^1H -NMR spectrum of product. c. The ^{13}C -NMR spectrum of product.). Taxol from the 50 ml reaction system was purified by HPLC then dissolved in CDCl_3 and confirmed by ^1H -NMR and ^{13}C -NMR analysis.


a




b




c




d




Supplementary Figure 2. Sequence and structure alignments of DBAT with other BAHD members. (a) Sequence alignment of DBAT with other BAHD members. The two conserved HXXXD and DFGWG motifs are marked in red boxes; the identical and similar residues are colored in green and pink, respectively. Accession numbers are as follows: DBAT, Q9M6E2.1; HCT, PDB: 4G22; HCT, PDB: 4KE4; PvHCT2, PDB: 5FAL; Vinorine synthase, PDB: 2BGH; Dm3MaT, PDB: 2E1U. (b) The structure of the HCT that was used as a template for DBAT homology modeling. (c) The structure of the predicted DBAT. (d) Structure alignment of DBAT with HCT (PDB: 4G22). HCT was colored in yellow, DBAT was colored in green.



Supplementary Figure 3. Evaluation of the predicted structure of DBAT by Ramachandran plot.



Supplementary Figure 4. Distribution of hydrophobicity and electronegativity residues in HCT and DBAT. (a) The front side of HCT. (b) The back side of HCT. (c) The front side of DBAT. (d) The back side of DBAT. (e) Electronegativity residue analysis of HCT. (f) Electronegativity residue analysis of DBAT. Residues were colored from red for negative potential, through white for near neutral, to blue for positive potential.



Supplementary Figure 5. The front side (left) and back side(right) of the predicted DBAT (DFGWG motif was colored in red, the predicted acyl acceptor substrate pocket was colored in green).

Supplementary Table 1. Comparison on the bioconversion of XDT to DT among different strains

Strains	Substrate Concentration (mg ml ⁻¹)	Reaction volume (ml)	XDT conversion rate (%)	DT yield (mg ml ⁻¹)	References
<i>Moraxella sp.</i>	0.25	2	~100	0.23	[23]
<i>Leifsonia shinshuensis</i>	0.5	2	~100	0.4	[24]
<i>Enterobacter sp.</i>	2.0	25	45	0.76	[25]
<i>Cellulosimicrobium cellulans</i>	0.5	100	91	0.3~0.4	[26]
Recombinant <i>Pichia pastoris</i>	15	1,000	~83	10.58	[32]
Recombinant <i>Pichia pastoris</i>	15*	10,000	~83	9.82**	[32]

*XDT_{ex} (containing 71.08% XDT, 10.67% 7-β-xylosyl-10-deacetylcepholamanine and 12.05% 7-β-xylosyl-10-deacetyltaxol C, w/w). **DT_{ex} (DT, 7.54; 10-deacetylcepholamanine, 1.05; 10-deacetyltaxol C, 1.23; mg ml⁻¹).

Supplementary Table 2. Specific activities of the six recombinant DBATs

Enzyme activity	<i>Taxus cuspidata</i>	<i>Taxus brevifolia</i>	<i>Taxus x media</i>	<i>Taxus canadensis</i>	<i>Taxus baccata</i>	<i>Taxus wallichiana var.</i>
(U mg ⁻¹) (10-DAB)	206.6±6.7	214.9±15.6	198.7±7.5	41.5±8.2	1.1±0.4	215.7±8.5
(U mg ⁻¹) ×10 ⁻¹ (DT)	2.60±0.21	2.64±0.10	1.79±0.06	0.38±0.04	0.03±0.06	1.82±0.06

The data represent the means±s.d., n=3.

Supplementary Table 3. ¹H (500 MHz) and ¹³C (125 MHz) NMR data for product ② (CDCl₃)

Position	$\delta_{\text{H,mult}}(J \text{ in Hz})$	δ_{C}	Position	$\delta_{\text{H,mult}}(J \text{ in Hz})$	δ_{C}
1		78.9	4-O-C*OCH ₃		170.3
2	5.68,d (7.0)	74.9	4-O-COC*H ₃	2.36,s	22.6
3	3.79,d (7.0)	45.6	10-O-C*OCH ₃		171.3
4		81.1	10-O-COC*H ₃	2.28,s	20.8
5	4.94,dd (9.0, 2.0)	84.3	1'		172.8
6	2.55, m, 1.88,m	35.6	2'	4.80, brs	73.1
7	4.40,dd (9.0, 6.0)	72.2	3'	5.78,d (9.0, 2.0)	55.0
8		58.6	4'		137.9
9		203.6	5'and9'	7.49,d (7.5)	127.0
10	6.27,s	75.5	6'and8'	7.43,t (7.5) ^a	128.7
11		133.1	7'	7.36,d (7.5)	128.4 ^a
12		142.0	1''		167.1
13	6.23,dd	72.4	2''		133.5
14	2.31,m, 2.27,m	35.7	3''and7''	7.73,d (7.5)	127.1
15		43.2	4''and6''	7.42,t (7.5) ^a	129.0 ^a
16	1.24,s	26.8	5''	7.51,d (7.5) ^a	131.9
17	1.14,s	21.8	1'''		167.0
18	1.80,s	14.8	2'''		128.4 ^a
19	1.69,s	9.5	3'''and7'''	8.13,d (7.5)	130.2
20	4.30,d(10.5), (10.5)	4.19,d 76.5	4'''and6'''	7.52,t (7.5) ^a	129.1 ^a
NH	6.98,d (9.0)		5'''	7.61,d (7.5)	133.7

^aOverlapping signals.

Supplementary Table 4. Activities of DBAT and its mutants obtained by alanine scanning against 10-DAB and DT

	DT		10-DAB	
	U mg ⁻¹ (×10 ⁻²)	Relative activity(%)	U mg ⁻¹ (×10)	Relative activity (%)
Con	26.00(±1.12)	100.00	20.66(±0.67)	100.00
S351A	25.45(±1.91)	97.87	19.56(±1.27)	94.69
G38A	37.69(±0.88)**	144.95	18.82(±0.51)	91.09
S396A	23.59(±1.32)	90.72	18.99(±0.48)	91.91
R40A	21.06(±0.79)	81.00	18.82(±0.96)	91.08
N353A	15.28(±0.44)	58.77	17.64(±0.22)	85.38
E41A	14.48(±0.07)	55.71	14.81(±0.46)	71.70
C165A	16.15(±0.26)	62.13	13.16(±0.36)	63.68
F160A	6.34(±0.07)	24.37	12.50(±0.09)	60.49
F301A	41.38(±1.12)**	159.17	9.75(±0.32)	47.18
P37A	2.78(±0.02)	10.71	8.00(±0.10)	38.72
F400A	1.32(±0.02)	5.07	3.58(±0.02)	17.32
F44A	0.22(±0.01)	0.85	1.89(±0.01)	9.15
G359A	2.84(±0.03)	10.92	1.67(±0.01)	8.06
I164A	0.19(±0.01)	0.72	0.25(±0.01)	1.20
G361A	ND	ND	ND	ND
R363A	ND	ND	ND	ND

The data represent the means±s.d., *n*=3. **P*<0.05 vs Control, ***P*<0.01 vs Control (Student's *t*-test). ND: Not detected.

Supplementary Table 5. Activities of Gly³⁸ saturation mutants against DT

	U mg ⁻¹ (×10 ⁻²)	Relative activity (%)
DBAT	26.00(±1.12)	100.00
G38R	56.88(±3.11)**	218.77
G38S	54.42(±2.02)**	209.32
G38D	49.79(±1.76)**	191.52
G38H	47.01(±0.97)**	180.81
G38A	41.44(±2.98)**	159.38
G38N	28.40(±1.70)	109.21
G38T	24.70(±0.67)	95.01
G38P	22.37(±0.16)	86.04
G38M	21.62(±0.27)	83.16
G38Q	17.37(±1.10)	66.79
G38E	16.79(±0.08)	64.59
G38W	13.21(±0.09)	50.80
G38Y	11.10(±0.04)	42.68
G38V	11.02(±0.01)	42.37
G38C	10.68(±0.10)	41.07
G38I	9.99(±0.01)	38.42
G38L	7.71(±0.04)	29.66
G38F	5.67(±0.01)	21.81
G38K	ND	ND

The data represent the means±s.d., *n*=3. **P*<0.05 vs Control, ***P*<0.01 vs Control (Student's *t*-test). ND: Not detected.

Supplementary Table 6. Activities of Phe³⁰¹ saturation mutants against DT

	U mg ⁻¹ ($\times 10^{-2}$)	Relative activity (%)
DBAT	26.00(± 1.12)	100.00
F301V	74.10(± 8.45)**	285.00
F301C	47.22(± 3.42)**	181.60
F301A	41.60(± 1.98)**	160.00
F301M	35.10(± 1.95)*	135.00
F301L	33.18(± 1.69)*	127.62
F301T	31.20(± 1.52)*	120.00
F301S	30.06(± 1.37)	115.62
F301Y	25.47(± 1.02)	97.96
F301G	18.80(± 0.54)	72.30
F301R	13.95(± 0.31)	53.67
F301H	10.02(± 0.15)	38.52
F301W	7.23(± 0.08)	27.79
F301I	7.02(± 0.09)	27.00
F301K	0.56(± 0.02)	2.16
F301P	0.11(± 0.02)	0.41
F301D	0.16(± 0.01)	0.60
F301Q	0.10(± 0.01)	0.40
F301E	0.16(± 0.02)	0.60
F301N	0.13(± 0.02)	0.50

The data represent the means \pm s.d., $n=3$. * $P<0.05$ vs Control, ** $P<0.01$ vs Control (Student's *t*-test).

Supplementary Table 7. Yields of Taxol in the two enzyme coupled catalytic system

Volume	1 ml	10 ml	50 ml
Taxol yield ($\mu\text{g ml}^{-1}$)	657.32 \pm 13.15	637.24 \pm 5.10	635.35 \pm 6.27

The data represent the means \pm s.d., $n=3$.

Supplementary Table 8. Cytotoxicities of Taxol and its analogues against human cancer cells (MTT method)

Compounds	IC ₅₀ (μM)				
	HCT116	NCI-H460	MGC803	HepG2	MCF-7
Taxol	0.0109	0.0211	0.00772	0.0691	0.00930
DT	0.0780	0.482	0.0508	0.482	0.0972
XDT	0.476	3.22	0.491	5.42	3.81

Note: HepG2, human hepatocellular liver carcinoma cell line; MCF-7: human breast carcinoma cell line; NCI-H460: human lung carcinoma cell line; HCT116: human colon carcinoma cell line; MGC803: human stomach carcinoma cell line.

Supplementary Table 9. The gradient elution conditions for 10-DAB and baccatin III analysis

Time (min)	Acetonitrile (%)	Water (%)
0	28	72
15	40	60
30	40	60
33	100	0
43	100	0
46	28	72
51	28	72

Supplementary Table 10. The gradient elution conditions for XDT, DT and Taxol analysis

Time (min)	Acetonitrile (%)	Water (%)
0	28	72
15	40	60
16	44	56
26	44	56
36	48	52
38	100	0
48	100	0
49	28	72
59	28	72

Supplementary Table 11. The linear equations of baccatin III, DT and Taxol

	Linear equations	Correlation coefficient
Baccatin III	$Y=43291X+35693$	$R^2=0.9999$
DT	$Y=66664X+175819$	$R^2=0.9995$
Taxol	$Y=148089X+41221$	$R^2=0.9996$

Supplementary Table 12. Primer sequences. The primers were used for construction the alanine mutants and saturation mutants

Primers	Sequences (5'→3', the corresponding mutant bases were labeled underlined)
37 AF	TGACAATCTAG <u>C</u> AGGGGTGAG
37 AR	CTCTACCCCT <u>G</u> CTAGATTGT
38AF	GACAATCTACCAG <u>C</u> GGTGAGAG
38AR	TTTTCTCTAC <u>C</u> GCTGGTAGA
40AF	CCAGGGGTG <u>G</u> CAGAAAACATT
40AR	AAATGTTTTCT <u>G</u> CCACCCCTG
41AF	CAGGGGTGAGAG <u>C</u> AAACATTT
41AR	AAAATGTTT <u>G</u> CTCTCACCCTG
44AF	AGAAAACATT <u>G</u> CTAACACCTTG
44AR	AAGGTGTTA <u>G</u> CAATGTTTTCT
160AF	GGTGAGT <u>G</u> CCTGCCATGGTATATG
160AR	CCATGGCAG <u>G</u> CACTACCCCTAC
162AF	TTTCTG <u>C</u> GCTGGTATATGTGATG
162AR	CATATACCAG <u>C</u> GCAGAAACTCACC
164AF	CCATGGT <u>G</u> CATGTGATGGACTAG
164AR	CATCACAT <u>G</u> CACCATGGCAGAAAC
165AF	CATGGTATAG <u>C</u> TGATGGACTAGG
165AR	AGTCCATCAG <u>C</u> TATACCATGGCAG
301A F	GGATACTACGGTAAT <u>G</u> CTGTTGG
301A R	ATACGGTACCAACAG <u>C</u> ATTACC
351AF	TCAGATGAG <u>G</u> CTATCAATTATG
351AR	TAATTGATAG <u>C</u> CTCATCTGATC
353AF	TGAGAGTATC <u>G</u> CTTATGAAAAC
353AR	TGTTTTCATAAG <u>C</u> GATACTCTC
359AF	AACATAGTT <u>G</u> CA ¹ TTTGGTGAT
359AR	CACCAAAT <u>G</u> CAACTATGTTTTCA
361AF	GTTGGATTT <u>G</u> CTGATCGAAG
361AR	CCTTCGATCAG <u>C</u> AAATCCAAC
363AF	TTTGGTGAT <u>G</u> CAAGGCGATTG
363AR	AATCGCCTT <u>G</u> CATCACCAAATC
396AF	AGTCGTGCAAG <u>C</u> TATTTTCTTTTC
396AR	GAAAATAAG <u>C</u> TGACGACTGAAAC
400AF	TATTTTCTT <u>G</u> CCATACGACCTCC
400AR	GAGGTCGTAT <u>G</u> GCAAGAAAATAAC
38NF	TACCANN <u>K</u> GTGAGAGAAAACATT
38NR	TCTCTCAC <u>M</u> NNTGGTAGATTGTC
301NF	CGGTAAT <u>N</u> NKGTTGGTACCGTATG
301NR	GTACCAAC <u>M</u> N ¹ NATTACCGTAGTAT